480 research outputs found
Reassessing the Reassessment of suPAR in Glomerular Disease
No full textsponsorship: Jochen Reiser is an inventor on pending and issued patents related to anti-proteinuric therapies. He stands to gain royalties from their present and future commercialization. He is also a co-founder and advisor to TRISAQ, a biotechnology company. The Associate Editor Nada Alachkar declares that, despite having previously published with Jochen Reiser, the review process was handled objectively and no conflict of interest exists. Bjorn K. I. Meijers declares no conflict of interest. (TRISAQ, a biotechnology company)status: Publishe
Faculty Opinions recommendation of Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.
No full textFaculty Opinions recommendation of Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.
No full textFaculty Opinions recommendation of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
No full text
Faculty Opinions recommendation of Cathepsin L is crucial for the development of early experimental diabetic nephropathy.
No full textFaculty Opinions recommendation of A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
No full textFaculty Opinions recommendation of The emergence of the glomerular parietal epithelial cell.
No full text
Faculty Opinions recommendation of Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family.
No full text- …
